Why the study?
Does the ACURATE neo transfemoral transcatheter heart valve provide safe and effective outcomes at 30 days in an unselected all-comers population with severe aortic stenosis?
Population
1,000 patients with severe aortic stenosis, mean age 81.1±5.2 years, logistic EuroSCORE II 6.6±7.5%, STS…
Design
Cohort
Follow-up
30-day
Authors
Loading...
Low event rates support ACURATE neo feasibility in severe AS; leaves open randomized comparisons to current valves.
Does the ACURATE neo transfemoral transcatheter heart valve provide safe and effective outcomes at 30 days in an unselected all-comers population with severe aortic stenosis?
The ACURATE neo prosthesis demonstrated good clinical outcomes with very low complication rates, including 1.4% 30-day mortality and 8.3% new pacemaker rate, in a real-world all-comers population with severe aortic stenosis.
Möllmann et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: